Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Pihlajalinna Plc’s disposal of own shares based on the share-based incentive programme

Pihlajalinna Plc                            Stock Exchange Release          25 February 2021 at 11.45 a.m. Pihlajalinna Plc’s disposal of own shares based on the share-based incentive programme A total of 26,546 treasury shares of Pihlajalinna Plc has been conveyed on 25 February 2021 without consideration to the key persons of the company based on the performance-based earning period 2020 of the share-based incentive programme according to the terms and conditions of the plan. The decision of the Board of Directors is based on a share issue authorization granted by the Annual

Hectic time for FVB in the UK

FVB in the UK has had a hectic time with the implementation of two major district heating projects. FVB has recently provided design services for the development of a large district heating network that will use residual heat supplied by the SELCHP Energy from Waste plant. The heat network is designed to supply a heating output of up to 30 MW for the supply of heat to both residential and commercial properties in the London Brough of Bermondsey district in southeast London. The project is receiving approximately £5 million of HNIP (Heat Network Investment Project) funding and is a key

Resolutions of Loudspring Plc's Extraordinary General Meeting

Loudspring Plc                                           Company Release 25 February 2021 at 11.30 (EET) Resolutions of Loudspring Plc's Extraordinary General Meeting The Extraordinary General Meeting of Loudspring Plc was held on 25 February 2021 in Helsinki. A total of 6 shareholders, 5,033,591 class A shares, 3,213,181 class K shares and 69,297,211 votes were represented in the meeting. The Extraordinary General Meeting resolved on the following issues: Authorizing the Board of Directors to decide on issuance of shares, options and other special rights entitling to

DNB Markets - Episurf Medical: Moving forward despite Covid-19

The company’s overall Q4 report (19 February) was strong, given the headwind among almost all elective procedures in Q4. However, underlying sales still increased YOY in 2020, a good sign. During the year, the amount of published clinical data increased (and should continue to rise in 2021) and this strengthens the company’s competitive position. Focus going forward will be on the EPIC-knee trial and the patellofemoral implant aimed to be filed in the US this year. We have lifted our fair value for the shares to SEK2.5–8 (previously SEK1.9–6.5).Q4 earnings hurt by the pandemic. Sales of

Nordic Nanovector ASA - Share capital increase registered

Oslo, Norway, 25 February 2021 Reference is made to the stock exchange announcement on 23 February 2021 regarding the successful completion of Nordic Nanovector ASA's (OSE: NANOV) (the "Company") private placement of new shares (the "Private Placement"). The share capital increase pertaining to the 15,878,122 new shares, each with a nominal value of NOK 0.20, to be issued in the Private Placement (the "New Shares") has been registered in the Norwegian Register of Business Enterprises (the "NRBE") on 25 February 2021, and the Company's share capital has been increased with NOK 3,175,

Holding(s) in Company

TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(to besent to the relevantissuer and tothe FCA in MicrosoftWord format ifpossible)[i] 1a. Identity of the EnQuest PLCissuer or theunderlying issuer ofexisting sharesto which votingrights areattached[ii]:1b. Please indicateif the issuer isa non-UK issuer (please mark withan "X" ifappropriate)Non-UK issuer2. Reason for thenotification (pleasemark theappropriate box orboxes with an"X")An acquisition or

NoHo Partners launches new co-operation negotiations to adapt its operations to restaurant closures

NoHo Partners PlcSTOCK EXCHANGE RELEASE 25 February 2021 at 10:45NoHo Partners launches new co-operation negotiations to adapt its operations to restaurant closuresNoHo Partners Plc will start new negotiations in accordance with the Co-operation Act in order to adjust its operations to the closure measures concerning the restaurant industry published by the Finnish Government today, which will enter into force on March 8, 2021. The aim of the negotiations is to minimize the economic impact of the COVID-19 pandemic.The co-operation negotiations cover the entire Group's personnel, i.e.

Ortoma launches new website highlighting market leading AI-assisted surgical solutions

Ortoma is now entering the commercialization phase of Ortoma Treatment Solution™ (OTS™) its AI assisted surgical technology platform for planning and positioning of orthopaedic implants. To emphasize some of the key features, the company has launched a new website: www.ortoma.comOTS™ is an orthopedic digital, server-based integrated AI platform designed to optimize patient outcomes through surgical planning, precision surgical navigation, post-operative verification, and follow-up. This platform is used at the point of care and provides immediate integration into the hospital system. The

Nordea Bank Abp: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act

Nordea Bank AbpStock exchange release – Major shareholder announcements25 February 2021 at 10.30 EET Nordea Bank Abp has on 24 February 2021 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights crossed the threshold of 5 per cent on 23 February 2021. According to the notification, the total number of Nordea Bank Abp’s shares and voting rights held directly or through financial instruments by BlackRock, Inc. and its funds was 5.06 per cent on 23

Ahlstrom-Munksjö’s Annual & Sustainability Report 2020 has been published

AHLSTROM-MUNKSJÖ OYJ, ANNUAL FINANCIAL REPORT, February 25, 2020 at 10:30 a.m. EET Ahlstrom-Munksjö has today published its Annual & Sustainability Report 2020 on the company’s website http://www.ahlstrom-munksjo.com. “In 2020, we were successful in improving our result and developing our business despite the unprecedented challenges caused by the coronavirus pandemic. Our quick response to the pandemic demonstrated our agility, worldwide teamwork and business mindset combined with a sense of responsibility. The offer is evidence of the good and hard work we have done, and our success

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 49 - 25 FEBRUARY 2021 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90/2020. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451

Approval of Mellozzan (melatonin)

The pharmaceutical Mellozzan tablets 0.5mg, 1mg, 2mg, 3mg, 4mg and 5mg, has been approved for sale in Sweden by the Medical Products Agency.Mellozzan is a prescription drug used to treat insomnia in children 6 - 17 years of age with ADHD where other sleep support measures are not sufficient. It can also be taken by adults to treat the effects of jet lag for a short time. Mellozzan contains the hormone melatonin, a synthetic form of the body's own hormone that the brain produces to promote sleep. Medicines containing melatonin are available in Sweden in the form of prolonged-release

Tele2 IoT launches Private Interconnect in partnership with Equinix

Tele2 IoT expands its portfolio with Private Interconnect, in partnership with the digital infrastructure company Equinix. Private Interconnect offers next level security, allowing IoT customers to expand their safety solution by connecting to Equinix's global Interconnection service, Equinix Fabric. This enables IoT customers to directly, securely, and dynamically connect to distributed infrastructure and digital ecosystems using a single port.When it comes to IoT, security is of utmost importance. Tele2 is opening up dedicated fiber for IoT customers who find the public Internet doesn’t

Impact of financial restructuring measures on equity and preliminary information on the result and financial position for the financial year 2020

Delete Group Oyj  Stock Exchange Release 25 February 2021 at 10.00 (EET)On 16 November 2020, Delete Group Oyj ("Delete") announced it had initiated certain voluntary restructuring measures, which included, among others, a restructuring of its EUR 110,000,000 notes due 2021. On 15 January 2021, Delete announced the successful completion of a written procedure regarding the senior secured notes, as proposed on 16 December 2020. On 16 January 2021, an extraordinary general meeting approved a new share issue of EUR 10 million in order to raise capital for a partial redemption of the

Amendment of terms of voluntary cash offer by Lesaffre to acquire all shares in NattoPharma

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Oslo, 25[th] February 2021: Reference is made to the press release dated 15 February 2021 regarding Compagnie des Levures Lesaffre's ("Lesaffre" or the "Offeror") intention to launch a voluntary cash offer for all outstanding shares of NattoPharma ASA ("NattoPharma" or the "Company") at an offer price of NOK 30 per share (the "Offer"). Lesaffre and NattoPharma have agreed to make certain amendments to the Offer, as

STRAX: Year-end report for the financial year 2020

STRAX doubled online sales and delivered a record year in EBITDA after successfully launching the Health & Wellness product category·The Group’s sales for the period January 1 – December 31, 2020, amounted to MEUR 112 (114), with a gross margin of 26.3 (24.5) percent. · The Group’s result for the period January 1 – December 31, 2020, amounted to MEUR 0.7 (-1.7) corresponding to EUR 0.01 (-0.01) per share.The result for the period was negatively affected by MEUR 2.5 (2.4) related to the decline in value of the Zagg shares.EBITDA for the period January 1 – December 31, 2020, amounted

Ayima Group AB - Year End Report 2020

Q4: Oct - Dec 2020 · A positive EBITDA for the quarter of 13.2 MSEK (11.2). An increase of 17% from the corresponding period in 2019 and a 911% increase from Q3, 2020 · Profit after tax for the quarter was 9.9 MSEK (0.3), a large increase from the corresponding period in 2019 · Gross Profit amounted to 29.5 MSEK (34.3), a decrease of 14% from the corresponding period in 2019 but an increase of 25% from Q3, 2020 · Total Revenue for the quarter amounted to 47.9 MSEK (48.7) a decrease of 2% from the corresponding period in 2019 but an increase of 60% from Q3, 2020 · Operating

BioStock: Coegin Pharma’s clinical development in actinic keratosis

Actinic keratosis (AK) is one of the most common skin disorders and can be a first step in the development of skin cancer. Patients undergoing conventional AK treatments frequently experience pain, bleeding, inflammation, and scarring. Consequently, new and better treatment options to reduce patient side effects such as skin damage are high demand. The Nordic biotech Coegin Pharma will soon start clinical evaluation of its candidate AVX001 as a potential new and better treatment of AK. BioStock was able to speak with the lead clinician in the clinical program, Professor Merete Hædersdal, to

MOS MOSH and Polygiene crush competition with the perfect men’s shirt

The fashion brand MOS MOSH now launch their new men’s line MOS MOSH Gallery by introducing shirts and tees for modern men on the go. Their spring collection 2021 is available now and these well-tailored styles have the added value of the Stays Fresh technologies Polygiene OdorCrunch and BioStatic. By taking the functionalities that work well in athletic wear and mix it with fashion, the result is a shirt without odor that stays fresh even after a long day at work. “This is a great example of a brand with the same sustainable vison to change the view on garments from consumables to

Summary of Year-End Report January – December 2020, Dicot AB

Translation of Swedish press release Uppsala, February 25, 2021. A summary of the Interim report January – December 2020, for Dicot AB (publ) is now avalible on the company webbsite www.dicot.se .Fourth Quarter 2020 · Net sales amounts to KSEK 0 (556) · Earnings for the period amounts to KSEK -4,188 (-3,530). · Earnings per share -0.10 (-0.22) SEK January – December 2020 · Net sales amounts to KSEK 0 (631) · Earnings for the period amounts to KSEK -17,541 (-13,396). · Earnings per share -0.61 (-1.35) SEK Statement from the CEO The development plan for the

Bokslutskommuniké 1 JANUARI – 31 DECEMBER 2020 FLOWSCAPE TECHNOLOGY AB (publ), ORG.NR. 556725-4866

Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – december 2020. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående år. (This information is only available in Swedish)Januari – december 2020 i korthet, koncern FJÄRDE KVARTALET (OKTOBER-DECEMBER) · Nettoomsättningen uppgick till 8 627 (7 201) TSEK · Rörelseresultat före avskrivningar uppgick till 68 (-335) TSEK · Resultat efter finansiella poster uppgick till -5 848 (-7 271) TSEK · Kassan vid perioden utgång var 9 986 TSEK

Cinclus Pharma Appoints Christer Ahlberg as Chief Executive Officer

Stockholm, Sweden 25[th] February 2021: Cinclus Pharma Holding AB (“Cinclus Pharma”), a biopharmaceutical company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announced the appointment of Christer Ahlberg as Chief Executive Officer.  Christer has extensive experience in the pharmaceutical industry and joins from Sedana Medical where he has been CEO since 2017.Christer Ahlberg will assume the position during the summer of 2021, thereby replacing the company’s current CEO and co-founder Kjell Andersson, who becomes Chief Scientific

A Strong Quarter Completes a Strong Year

PowerCell Sweden AB grew its sales by 41 percent during the fourth quarter 2020, from MSEK 27.0 to MSEK 38.2. For the full year 2020 sales increased by 55 percent to MSEK 103.5 (66.9). Operating income before items affecting comparability for the fourth quarter weakened to MSEK -29.5 (-28.7) due to, among other things, continued aggressive investments to grow the business within new segments and to negative currency effects.“In terms of sales, the fourth quarter 2020 amounted to the strongest quarter in the company’s history and led to that PowerCell Sweden achieved total sales in excess

There are no items matching the current filter
There are no more items matching the current filter
Back to top